Cargando…

HLA‐A24:02 increase the risk of allopurinol‐induced drug reaction with eosinophilia and systemic symptoms in HLA‐B58:01 carriers in a Korean population; a multicenter cross‐sectional case‐control study

BACKGROUND: HLA‐B*58:01 is a well‐known risk factor for allopurinol‐induced severe cutaneous adverse reactions (SCARs). However, only a minority of HLA‐B*58:01 carriers suffer SCARs after taking allopurinol. The aim of this study was to investigate subsidiary genetic markers that could identify thos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Mi‐Yeong, Yun, James, Kang, Dong‐Yoon, Kim, Tae Hee, Oh, Min‐Kyung, Lee, Sunggun, Kang, Min‐Gyu, Nam, Young‐Hee, Choi, Jeong‐Hee, Yang, Min‐Suk, Han, Seung Seok, Lee, Hajeong, Cho, Hyun‐Jai, Yang, Jaeseok, Oh, Kook‐Hwan, Kim, Yon Su, Jung, Jae Woo, Lee, Kye Hwa, Kang, Hye‐Ryun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478421/ https://www.ncbi.nlm.nih.gov/pubmed/36176736 http://dx.doi.org/10.1002/clt2.12193

Ejemplares similares

248 HLA-B58 Does not Increase Allopurinol Hypersensitivity among Patients with Hematologic Malignancy
por: Jung, Jae-Woo, et al.
Publicado: (2012)

Allopurinol non-covalently facilitates binding of unconventional peptides to HLA-B*58:01
por: Huan, Xuelu, et al.
Publicado: (2023)

Allopurinol-Induced Stevens–Johnson Syndrome in Javanese Men With Positive HLA‐B*58:01
por: Ferdiana, Astri, et al.
Publicado: (2022)

HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
por: Sukasem, Chonlaphat, et al.
Publicado: (2016)

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies
por: Wu, Ran, et al.
Publicado: (2016)

HLA-B*58:01 allele is strongly associated with allopurinol-induced severe cutaneous adverse reactions in a Thai population
por: Jantararoungtong, Thawinee, et al.
Publicado: (2014)

Allopurinol-induced severe cutaneous adverse reactions: A report of three cases with the HLA-B(*)58:01 allele who underwent lymphocyte activation test
por: Kim, Eun-Young, et al.
Publicado: (2017)

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study
por: Ko, Tai-Ming, et al.
Publicado: (2015)

HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, Age and Sex Are Associated With Severity of Japanese COVID-19 With Respiratory Failure
por: Khor, Seik-Soon, et al.
Publicado: (2021)

Comparison between the HLA-B(∗)58 : 01 Allele and Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe Cutaneous Adverse Reactions
por: Saksit, Niwat, et al.
Publicado: (2017)

HLA-DRB1*07:01–HLA-DQA1*02:01–HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia
por: Kutszegi, Nóra, et al.
Publicado: (2017)

Validation of a Rapid, Robust, Inexpensive Screening Method for Detecting the HLA-B(*)58:01 Allele in the Prevention of Allopurinol-Induced Severe Cutaneous Adverse Reactions
por: Nguyen, Dinh Van, et al.
Publicado: (2017)

Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice
por: El Bissati, Kamal, et al.
Publicado: (2020)

HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children
por: Amstutz, Ursula, et al.
Publicado: (2013)

An HLA-C amino-acid variant in addition to HLA-B*27 confers risk for ankylosing spondylitis in the Korean population
por: Kim, Kwangwoo, et al.
Publicado: (2015)

Two Cases of Transfusion-related Acute Lung Injury Triggered by HLA and Anti-HLA Antibody Reaction
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Affinity Maturation of a T-Cell Receptor-Like Antibody Specific for a Cytomegalovirus pp65-Derived Peptide Presented by HLA-A*02:01
por: Lee, Se-Young, et al.
Publicado: (2021)

Novel glutathione-containing dry-yeast extracts inhibit eosinophilia and mucus overproduction in a murine model of asthma
por: Kim, Yun-Ho, et al.
Publicado: (2017)

Associations between the HLA-A polymorphism and the clinical manifestations of Behcet's disease
por: Kang, Eun Ha, et al.
Publicado: (2011)

HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02
por: Martín, Paloma, et al.
Publicado: (2015)

HLA and Disease Associations in Koreans
por: Ahn, Stephen, et al.
Publicado: (2011)

Associations of HLA‐C*01:02 and HLA‐B*46:01 with regorafenib‐induced erythema multiforme in Japanese patients with metastatic colorectal cancer
por: Fujita, Ken‐ichi, et al.
Publicado: (2023)

Clinical evaluation of a substitute of HLA-B*58:01 in different Chinese ethnic groups
por: Zhang, Xinju, et al.
Publicado: (2018)

A Case of Allopurinol-Induced Fixed Drug Eruption Confirmed With a Lymphocyte Transformation Test
por: Kim, Min-Hye, et al.
Publicado: (2012)

Molecular Analysis of HLA Class ll-Associated Susceptibility to Neuroinflammatory Diseases in Korean Children
por: Oh, Hyun Hee, et al.
Publicado: (2004)

Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population
por: Wang, Chuang-Wei, et al.
Publicado: (2022)

HLA-DRB1∗16:01 and HLA-DQB1∗05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma
por: Wang, Xu, et al.
Publicado: (2021)

Imputing Variants in HLA-DR Beta Genes Reveals That HLA-DRB1 Is Solely Associated with Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Kim, Kwangwoo, et al.
Publicado: (2016)

Liver transplantation in a child with acute liver failure resulting from drug rash with eosinophilia and systemic symptoms syndrome
por: Song, Seung Min, et al.
Publicado: (2013)

Independent association of HLA-DPB1*02:01 with rheumatoid arthritis in Japanese populations
por: Furukawa, Hiroshi, et al.
Publicado: (2018)

HLA-targeted sequencing reveals the pathogenic role of HLA-B*15:02/HLA-B*13:01 in albendazole-induced liver failure: a case report and a review of the literature
por: Liao, Jin-Mao, et al.
Publicado: (2023)

Prevalence of Toxocariasis and Its Risk Factors in Patients with Eosinophilia in Korea
por: Song, Hyun Beom, et al.
Publicado: (2020)

Acute kidney injury predicts all‐cause mortality in patients with cancer
por: Kang, Eunjeong, et al.
Publicado: (2019)

HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease
por: Hosseini, Ehteramolsadat, et al.
Publicado: (2023)

Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control
por: Murakoshi, Hayato, et al.
Publicado: (2018)

Characteristics and Clinical Significance of De Novo Donor-Specific Anti-HLA Antibodies after Kidney Transplantation
por: Jung, Hee-Yeon, et al.
Publicado: (2018)

Rapid Multiplex Genotyping of 20 HLA-A(*)02:01 Restricted Minor Histocompatibility Antigens
por: Romaniuk, Dmitrii S., et al.
Publicado: (2019)

The presentation of SARS-CoV-2 peptides by the common HLA-A(∗)02:01 molecule
por: Szeto, Christopher, et al.
Publicado: (2021)

Characterization of the novel HLA‐DQA1*02:01:14 allele by sequencing‐based typing
por: Cargou, Marine, et al.
Publicado: (2022)

Characterization of the novel HLA‐DPA1*02:01:21 allele by sequencing‐based typing
por: Cargou, Marine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3s5q5lqirrrjm9hqm2mvsfrdee